Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
09:35pm, Friday, 06'th Jun 2025
SAN DIEGO , June 6, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 a
Join Class Action to Recover Losses from UroGen Pharma Ltd. (URGN) – Contact Levi & Korsinsky Before July 28, 2025
06:45pm, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN
Investors in UroGen Pharma Ltd. (URGN): Protect Your Rights - Contact Levi & Korsinsky Before July 28, 2025
06:10pm, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd.
Levi & Korsinsky Notifies UroGen Pharma Ltd. (URGN) Shareholders of Class Action Lawsuit And July 28, 2025 Deadline
04:30pm, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
Levi & Korsinsky Notifies UroGen Pharma Ltd. (URGN) Investors - Lead Plaintiff Deadline on July 28, 2025
04:00pm, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain
Investors in UroGen Pharma Ltd. (URGN): Protect Your Rights - Contact Levi & Korsinsky Before July 28, 2025
12:15pm, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 06'th Jun 2025
LOS ANGELES , June 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to UroGen Pharma Ltd.
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
10:38am, Friday, 06'th Jun 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Phar
URGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against UroGen Pharma Ltd. - July 28, 2025 Deadline
09:00am, Friday, 06'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the
